[Skip to Content]
UCB - Aspiring to be the patient-centric biopharma leader
UCB Worldwide
Contact
Sitemap
Search
Home
Patients
Partners
Investors
Media
Job seekers
About UCB
Products
R & D
CSR
Magazine
Region
Corporate
Belgium
China
Germany
Greece
UK
US
Go
Overview
News
Therapy Areas
Resources
Events & Presentations
Editorial Guidelines
Press Contact
Magazine
Facts and Figures
Share
|
Total surface area of 5 100 m², including 800m² of laboratories
4 bioreactors with a total capacity of 3 200 litres
Mammalian cell cultures and the purification of related biotechnological products are used to produce between 40 and 60 kilos of active material per year
The new plant will have the same development capacity as a conventional plant, while having access to aqueous environments, excluding the use of solvents and reducing the use of chemical products
Operations are expected to begin in summer 2012
The plant will employ around one hundred qualified professionals
UCB's Braine-l'Alleud site currently employs over 1 500 people working in 18 buildings on a 51-hectare site
Asset Download
Download this page as a PDF
Download everything on this page (.zip format)